MARKET

XERS

XERS

XERIS PHARMACEUTICALS INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.21
-0.14
-1.35%
Opening 14:58 09/20 EDT
OPEN
10.34
PREV CLOSE
10.35
HIGH
10.81
LOW
9.84
VOLUME
162.32K
TURNOVER
--
52 WEEK HIGH
25.49
52 WEEK LOW
6.85
MARKET CAP
194.35M
P/E (TTM)
-2.5292
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of XERS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

XERS News

  • Xeris Pharmaceuticals Begins Dosing Patients in a Phase 2 Clinical Trial Evaluating Its Novel Fixed-Ratio Co-Formulation of Pramlintide-Insulin for Diabetes
  • Business Wire.1d ago
  • 25 Healthcare Stocks Moving In Wednesday's Pre-Market Session
  • Benzinga.09/11 12:21
  • Mizuho Maintains Buy on Xeris Pharmaceuticals, Lowers Price Target to $22
  • Benzinga.09/11 10:57
  • 80 Biggest Movers From Yesterday
  • Benzinga.09/11 09:11

More

Industry

Biotechnology & Medical Research
+0.58%
Pharmaceuticals & Medical Research
+1.11%

Hot Stocks

Name
Price
%Change

About XERS

Xeris Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing injectable and infusible drug formulations. It uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products. Its formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of formulations of peptides, proteins, antibodies and small molecules using commercially-available syringes, auto-injectors, multi-dose pens and infusion pumps. The Company is developing its lead product candidate, the Glucagon Rescue Pen, for the treatment of severe hypoglycemia in people with diabetes. It is also developing treatments for post-bariatric hypoglycemia, congenital hyperinsulinism, hypoglycemia-associated autonomic failure and exercise-induced hypoglycemia. Its Glucagon Rescue Pen offers a stable glucagon that is designed to be administered subcutaneously in a simple two-step process.
More

Webull offers Xeris Pharmaceuticals Inc (XERS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.